Previous Close | 1.3623 |
Open | 1.3623 |
Bid | 1.3515 |
Day's Range | 1.3511 - 1.3628 |
52 Week Range | 1.3387 - 1.5114 |
Ask | 1.3516 |
BOSTON, May 05, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2022 and reiterated full year 2022 product revenue guidance.
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
Vertex Pharmaceuticals Inc.'s Reshma Kewalramani made $15.2 million in her first full year as CEO of Massachusetts' fourth-largest life sciences employer. Vertex (Nasdaq: VRTX) disclosed Kewalramani's compensation in a securities filing late Thursday. Like all executives, Kewalramani's total pay is a combination of base salary, stock awards and other compensation.